Jeffrey Cooper speaks at PRIM&R

Jeffrey A. Cooper, MD, MMM will be speaking at PRIM&R’s 2012 Advancing Ethical Research Conference Dec. 3 through Dec. 6 in San Diego, Calif.

The annual Advancing Ethical Research Conference serves those involved in every facet of the research arena. The 2012 conference will bring together nearly 3,000 individuals from hospitals, universities and other research institutions, the federal government and industry. A series of 18 informational and inspirational plenary sessions will be offered, as well as participation in 150 practical workshops and didactic sessions.

Through his 25 years of experience in the field of human research subject protection, Cooper has greatly enhanced IRB efficiency while maintaining compliance and effectiveness. As an expert in international laws and standards to human research, Cooper will be participating in three different sessions during the conference, including:

  • Monday, Dec. 3 8:30 a.m. -4:45 p.m.
    IRB 301: Review and Application of the Regulatory Criteria for Approval
    In this exclusive session, Cooper will help attendees understand how to apply the criteria for IRB approval of research and provide the knowledge on how to guide the IRB in the application of the criteria for IRB approval.
  • Tuesday, Dec. 4 10:30 a.m. – 11:45 a.m.
    A9 Advanced: To Waive or not to Waive? That Is the Question
    During this session, Cooper will discuss the appropriate use of waivers. Attendees will review the regulatory applicability of waivers and explore a variety of cases in which a waiver would add more protections and help facilitate research.
  • Tuesday, Dec. 4 3:45 p.m.–5:00 p.m.
    B12 Basic: Is It Human Research? Is It Exempt? Determining When an Activity Must Undergo IRB Review
    As a co-facilitator and expert in the DHHS and FDA regulations, Cooper will provide attendees with the opportunity to become more familiar with the two distinct definitions of human subjects research found in the DHHS and FDA regulations. Attendees will also be able to discuss the differences between DHHS and FDA regulations regarding exempt research categories.

For more information on the conference, visit